SANTA CLARA, California, USA, July 8, 2026
Agilent Technologies has expanded its Altura High-Performance Liquid Chromatography (HPLC) portfolio with the launch of new Altura Size Exclusion Chromatography (SEC) and Altura PLRP-S columns, strengthening analytical capabilities for biopharmaceutical research, development, and manufacturing. The latest additions are engineered to support critical analytical workflows across a broad spectrum of biotherapeutic modalities, including monoclonal antibodies (mAbs), peptides, oligonucleotides, antibody-drug conjugates (ADCs), mRNA therapeutics, and other complex biologics. Designed with Ultra Inert technology, the new columns deliver enhanced peak shape, aggregate recovery, analytical sensitivity, reproducibility, and molecular characterization, helping scientists improve product quality assessment throughout drug development and commercial manufacturing. The portfolio expansion reflects Agilent’s continued investment in advanced analytical technologies that enable more accurate characterization of increasingly sophisticated biologic medicines while supporting regulatory-quality analytical workflows across the global biopharmaceutical industry.
Advanced Chromatography Solutions Enhance Biotherapeutic Analysis
The newly introduced Altura SEC and Altura PLRP-S columns address growing analytical challenges associated with modern biotherapeutic development. As biologic medicines become increasingly complex, pharmaceutical laboratories require highly sensitive chromatographic technologies capable of accurately evaluating protein aggregation, molecular weight confirmation, size distribution, and structural integrity. The Altura SEC columns build upon Agilent’s established AdvanceBio SEC platform by incorporating Ultra Inert technology, significantly improving aggregate recovery and chromatographic peak quality.
For GLP-1 peptide therapeutics, the columns demonstrate up to two-fold greater analytical sensitivity compared with competing inert chromatography columns, enabling improved detection of low-level impurities that are essential for maintaining product quality and patient safety. Meanwhile, the Altura PLRP-S columns have been optimized for demanding liquid chromatography-mass spectrometry (LC/MS) applications, supporting robust molecular weight confirmation and detailed characterization of protein therapeutics and other advanced biologic products.
Supporting Quality Control Across Complex Biopharmaceutical Modalities
Advertisement
The expanded Altura portfolio has been developed to support analytical testing across a wide range of emerging therapeutic modalities, including peptide therapeutics, monoclonal antibodies, antibody-drug conjugates, oligonucleotide medicines, and mRNA-based therapies. Applications such as aggregate characterization, drug-to-antibody ratio (DAR) determination, and molecular integrity assessment remain essential for evaluating the safety, stability, efficacy, and manufacturing consistency of next-generation biologics.
By delivering faster column conditioning, improved peak symmetry, enhanced reproducibility, and superior analytical sensitivity, the new chromatography solutions enable laboratories to generate high-quality analytical data throughout research, process development, quality control, and regulatory testing. Independent laboratory evaluations have also demonstrated excellent long-term performance across hundreds to thousands of sample injections, highlighting the columns’ durability and suitability for demanding pharmaceutical environments.
Integrated Analytical Platform Advances Biopharmaceutical Innovation
The latest product launch strengthens Agilent Technologies’ comprehensive portfolio of liquid chromatography instrumentation, analytical columns, laboratory software, and scientific workflow solutions supporting pharmaceutical innovation worldwide. When integrated with Agilent’s broader Ultra Inert liquid chromatography platform, the new Altura columns create a fully optimized analytical flow path designed to minimize sample interactions while maximizing reproducibility and analytical confidence. As the global biopharmaceutical sector continues to expand across precision medicines, cell and gene therapies, RNA therapeutics, and antibody-based treatments, demand for advanced analytical technologies capable of supporting increasingly complex characterization requirements continues to grow.
By expanding the Altura HPLC portfolio, Agilent provides researchers, contract development and manufacturing organizations (CDMOs), and pharmaceutical manufacturers with advanced analytical tools that improve workflow efficiency, strengthen product quality evaluation, and accelerate the development of innovative biologic therapies for patients worldwide.
Source: Agilent Technologies press release
